Pioneering science to transform patient lives through innovative immunology therapies
Nektar Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 1990, Nektar has led development in PEGylation technology — attaching polyethylene glycol (PEG) polymer chains to drug molecules to improve their pharmacokinetics. The company subsequently pivoted to immunology, developing novel small-molecule and biologic therapies for conditions including atopic dermatitis and multiple sclerosis. Its lead asset NKTR-0165 demonstrated strong Phase 2b results in eczema in early 2026. Nektar went public in 1994 (Nasdaq: NKTR).
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountFeb 2026
Jan 1994
Create a free account to see which investors have funded this company.
Create Free Account
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
